NCT02541604 · OUTCOME

Optimal Dose of Atezolizumab in Pediatric Adult Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: mg/kg
Interval / dispersion: Not reported
Time frame: From baseline up to approximately 42 months

What was measured

Atezolizumab was administered on Day 1 only for a cycle duration of 3 weeks.

Groups in this outcome

<18 Age (Years)

Participants \<18 Age (Years)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
<18 Age (Years)	69

Reported measurements

Source class 1

Values in mg/kg · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
<18 Age (Years)	15	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
15

denoms

counts
group Id
OG000
value
69
units
Participants

description

Atezolizumab was administered on Day 1 only for a cycle duration of 3 weeks.

groups

description
Participants \<18 Age (Years)
id
OG000
title
<18 Age (Years)

param Type

NUMBER

reporting Status

POSTED

time Frame

From baseline up to approximately 42 months

title

Optimal Dose of Atezolizumab in Pediatric Adult Participants

type

SECONDARY

unit Of Measure

mg/kg

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice